Real-World Experience of Bamlanivimab for Coronavirus Disease 2019 (COVID-19): A Case-Control Study

BACKGROUND: Coronavirus disease 2019 (COVID-19) has strained healthcare systems with patient hospitalizations and deaths. Anti-spike monoclonal antibodies, including bamlanivimab, have demonstrated reduction in hospitalization rates in clinical trials, yet real-world evidence is lacking. METHODS: We...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumar, Rebecca N, Wu, En-Ling, Stosor, Valentina, Moore, William J, Achenbach, Chad, Ison, Michael G, Angarone, Michael P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8083260/
https://www.ncbi.nlm.nih.gov/pubmed/33846730
http://dx.doi.org/10.1093/cid/ciab305

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8083260/
https://www.ncbi.nlm.nih.gov/pubmed/33846730
http://dx.doi.org/10.1093/cid/ciab305

Ejemplares similares